Private Placement Strengthens Funding Position Agenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of…
s clinical pipeline. The financing also includes purchase warrants that could generate an additional $255 million if fully exercised, bringing the total potential value of the transaction to $340 million
Leading Healthcare Investors Back the Deal The private placement was led by Commodore Capital, with participation from several existing and new institutional investors, including RA Capital Management, TCGX, Invus and Ligand Pharmaceuticals. According to the company, the proceeds will primarily be used to fund its Phase 3 ROBBIN clinical trial. Assuming all warrants are exercised, Agenus expects the financing to provide sufficient cash to support operations through the end of 2031.
Company Refocuses Clinical Development Strategy Alongside the financing announcement, Agenus said it plans to discontinue financial support for the BATTMAN Phase 3 study evaluating a treatment for late-line metastatic microsatellite stable (MSS) colorectal cancer. The move reflects the company’s decision to prioritise resources toward programmes it believes offer stronger long-term development opportunities. Capital Raise Supports Long-Term Pipeline The new financing provides Agenus with additional flexibility as it advances its late-stage clinical portfolio while extending its projected cash runway.